Euroimmun, a Revvity company, and Xpedite Diagnostics have partnered to offer DNA extraction protocols for point-of-care diagnostics.

Chongqing, China – The 21st edition of China Association of Clinical Laboratory Practice Expo (CACLP) and the 4th edition of China IVD Supply Chain Expo (CISCE) are scheduled to take place 16-18 March at Chongqing International Expo Center. The two tradeshows will be complemented by a diverse range of concurrent academic activities, starting on 15 March 2024.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Liquid biopsy firm SeekIn said Friday that it has entered into a strategic collaboration with Oncolnv, a fully-owned affiliate of Inspire2Live to expand the global accessibility of the firm's menu of cancer detection tests.

Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa) and Sysmex Corporation (President: Kaoru Asano) today announced that they have signed an agreement for the mutual supply of reagent raw materials owned by both companies (“the Agreement”). The Agreement is based on a basic agreement on business collaboration in the field of immunoassay*1 which the two companies signed in October 2023.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

PlumCare and Fabric Genomics said Thursday that they have partnered to integrate the Fabric AI platform with PlumCare’s FirstSteps newborn genome screening program in Greece.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

On December 1, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (referred to as the “Company” or “Mindray”, SZSE: 300760) announced the completion of its acquisition of a 75% stake in Germany-based DiaSys Diagnostic Systems GmbH (“DiaSys”). Upon completion, DiaSys is now recognized as a majority-owned subsidiary of Mindray.

Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa) and Sysmex Corporation (President: Kaoru Asano) today announced that they have entered into an agreement to expand their Contract Development and Manufacturing Organization (CDMO) partnership for Sysmex's Automated Immunoassay System HISCL™-Series to include the field of neurodegenerative diseases, following the discussion based on the Basic Agreement on Business Collaboration in the field of immunoassay signed in October 2023*.